AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2025
Mar 8, 2025
32883_dirs_2025-03-07_7973ca1f-b1ca-4b77-a2e3-28024932f177.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-03-04
Reporting Person: Tsuchimoto Kim R (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-04 | Stock Options | $31.70 | A | 11365 | Acquired | 2035-03-04 | Common Stock (11365) | Direct |
Footnotes
F1: Options vest 25% quarterly on March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025.
More from Monopar Therapeutics
Regulatory Filings
2026
May 29
Regulatory Filings
2026
May 19
Interim / Quarterly Report
2026
May 14
Regulatory Filings
2026
May 14
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 1
Annual Report
2026
Mar 27
Director's Dealing
2026
Mar 4
Board/Management Information
2026
Mar 2